Peter Kiener

Peter Alec Kiener was the founder of Zyngenia, Inc., founded in 2009, where the titles held included President, Chief Executive Officer & Director from 2009 to 2013.
Current jobs include Chairman at Resolve Therapeutics LLC; Director at AbCellera Boston, Inc.; Director at Wugen, Inc. since 2021; Director at Peptone Ltd. since 2022; Venture Partner at Bridge Valley Ventures LLP; and Venture Partner at Intermediate Capital Group Plc (Private Equity) since 2021.
Former jobs include Chief Executive Officer at Cereius, Inc. from 2019 to 2020; Director at GT Biopharma, Inc. from 2018 to 2019; Director at Receptor BioLogix, Inc.; Director at Adheron Therapeutics, Inc.; Independent Non-Executive Director at LAVA Therapeutics NV from 2023 to 2025; Director at Virdante Pharmaceuticals, Inc.; Director at Viral Logic Systems Technology Corp.; Director at Cirius Therapeutics, Inc. from 2019 to 2021; Independent Director at Cue Biopharma, Inc. from 2020 to 2026; Director at Itolerance, Inc. from 2001 to 2024; Director at TetraGenetics, Inc. from 2015 to 2022; Independent Director at Pieris Pharmaceuticals, Inc. from 2018 to 2024; Head-Global Research & Development at Bristol Myers Squibb Co. from 1983 to 2001; Executive Vice President-Research & Development at MedImmune LLC; Executive Vice President at AstraZeneca PLC in 2009; Principal at the University of Oxford; Assistant Professor at the University of North Texas from 1982 to 1983; Research Associate at the University of Massachusetts from 1978 to 1982; Chief Science Officer at Ambrx, Inc. from 2013 to 2014; and Chief Scientific Officer at Sucampo Pharmaceuticals LLC from 2014 to 2018.
Education includes a doctorate from the University of Oxford conferred in 1978 and an undergraduate degree from the University of Lancaster conferred in 1973.